Authors

Dr. Manja Epping

Partner

Read More

Evelyne Friedel

Partner

Read More

Matthew Royle, Ph.D.

Partner

Read More
Authors

Dr. Manja Epping

Partner

Read More

Evelyne Friedel

Partner

Read More

Matthew Royle, Ph.D.

Partner

Read More

30 May 2019 |

Recent legislative developments affecting biologics and biosimilars

Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets. Recently, a flurry of proposed legislation has threatened to drastically alter the US regulation of and policies on wide ranging topics such as drug pricing, mandatory licensing, patent thickets, and the availability of post-grant proceedings.

In session 2 of this series we focus on key factors decision makers need to be aware of when considering currently pending legislation, including:

  • Key provisions of proposed legislation
  • European perspectives and approaches to similar issues

View session 1


Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Pills
Life sciences & healthcare

Biologics and biosimilars litigation update

25 November 2020
Quick read

by Matthew Royle, Ph.D. and Dr. Nora E. Wessendorf, LL.M. (Washington)

Click here to find out more
centrifuge-machine
Life sciences & healthcare

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

27 July 2020
QUICK READ

by multiple authors

Click here to find out more
woman-with-scientific-model
Life sciences & healthcare

Everything biologic and biosimilar in-house counsel need to know about COVID-19

29 April 2020

by multiple authors

Click here to find out more

Related events

There are no upcoming events